N-Glycosylated type Ⅱ collagen peptides as therapeutic saccharide vaccines for rheumatoid arthritis

作     者：Dake Liu Shuyan Liu Fanlei Hu Zhongtang Li Zhongjun Li Dake Liu;Shuyan Liu;Fanlei Hu;Zhongtang Li;Zhongjun Li

作者机构：State Key Laboratory of Natural and Biomimetic DrugsSchool of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Rheumatology and ImmunologyPeking University People’s HospitalBeijing 100044China 

出 版 物：《Chinese Chemical Letters》 (中国化学快报（英文版）)

年 卷 期：2024年第35卷第5期

页      面：197-200页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China(Nos.81930097,21977005,82151223) supported by the National Key R&D Program of China(No.2022YFF1203005) 

主　　题：Rheumatoid arthritis TypeⅡcollegan Glycosylation N-Glycosylated altered peptides Saccharide vaccines 

摘      要：The interaction among type Ⅱ collagen(CⅡ),human DR4 major histocompatibility complex type Ⅱ molecule(MHC Ⅱ)and T-cell receptor(TCR)is associated with the development of rheumatoid arthritis(RA).The activation of T cells can be reduced through exposure to modified CⅡ(263-272)glycopeptide fragment via competitive inhibition with *** this work,30 peptides based on the sequence of CⅡ(263-272)were prepared and evaluated for their binding to DR4 protein by surface plasmon resonance(SPR)*** effect on the secretion of pro-inflammatory factors by the spleen cells in collagen induced rheumatoid arthritis(CIA)mouse was also *** N-glycosylated CⅡ peptides were identified to have strong binding to the human recombinant DR4 protein and weak proinflammatory *** glycopeptides could be developed as therapeutic saccharide vaccines for the treatment of rheumatoid arthritis(RA).